Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 27;14(10):1844-1861.
doi: 10.4254/wjh.v14.i10.1844.

Natural history and management of liver dysfunction in lysosomal storage disorders

Affiliations
Review

Natural history and management of liver dysfunction in lysosomal storage disorders

Moinak Sen Sarma et al. World J Hepatol. .

Abstract

Lysosomal storage disorders (LSD) are a rare group of genetic disorders. The major LSDs that cause liver dysfunction are disorders of sphingolipid lipid storage [Gaucher disease (GD) and Niemann-Pick disease] and lysosomal acid lipase deficiency [cholesteryl ester storage disease and Wolman disease (WD)]. These diseases can cause significant liver problems ranging from asymptomatic hepatomegaly to cirrhosis and portal hypertension. Abnormal storage cells initiate hepatic fibrosis in sphingolipid disorders. Dyslipidemia causes micronodular cirrhosis in lipid storage disorders. These disorders must be keenly differentiated from other chronic liver diseases and non-alcoholic steatohepatitis that affect children and young adults. GD, Niemann-Pick type C, and WD also cause neonatal cholestasis and infantile liver failure. Genotype and liver phenotype correlation is variable in these conditions. Patients with LSD may survive up to 4-5 decades except for those with neonatal onset disease. The diagnosis of all LSD is based on enzymatic activity, tissue histology, and genetic testing. Enzyme replacement is possible in GD and Niemann-Pick types A and B though there are major limitations in the outcome. Those that progress invariably require liver transplantation with variable outcomes. The prognosis of Niemann-Pick type C and WD is universally poor. Enzyme replacement therapy has a promising role in cholesteryl ester storage disease. This review attempts to outline the natural history of these disorders from a hepatologist's perspective to increase awareness and facilitate better management of these rare disorders.

Keywords: Children; Cholesteryl ester; Gaucher; Lysosomal; Niemann-Pick; Wolman.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No conflict of interests.

Figures

Figure 1
Figure 1
Pathogenesis of Gaucher disease. GD: Gaucher disease.
Figure 2
Figure 2
Histology of Gaucher disease. Red arrow shows Gaucher cells.
Figure 3
Figure 3
Pathogenesis of Niemann-Pick disease types A, B, and C. NPD: Niemann-Pick disease.
Figure 4
Figure 4
Fundus examination showing a cherry red spot (red arrow) with a background of white retina.
Figure 5
Figure 5
Histology in Niemann-Pick disease type B. Red arrow shows a foamy vacuolated histiocyte.
Figure 6
Figure 6
Infant with Niemann-Pick disease type C presenting as cholestasis, dilated abdominal veins, and massive hepatosplenomegaly.
Figure 7
Figure 7
Pathogenesis of lysosomal acid lipase deficiency. CESD: Cholesteryl ester storage disease; VLDL: Very low-density lipoproteins.
Figure 8
Figure 8
Computed tomography of the abdomen in an infant with Wolman disease showing bilateral adrenal calcifications.

References

    1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254. - PubMed
    1. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151–156. - PubMed
    1. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol. 1997;10:657–689. - PubMed
    1. Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, Phadke SR, Sachdeva A, Verma IC, Mistry PK Gaucher Disease Task Force. Diagnosis and Management of Gaucher Disease in India - Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018;55:143–153. - PubMed
    1. Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36:543–553. - PMC - PubMed